In light of the recent approval (May 2020) of dupilumab for AD in pediatric patients between the ages of 6 and 11 years of age, can you review the evidentiary basis for this approval based on clinical trials, and the practical implications?

Name: In light of the recent approval (May 2020) of dupilumab for AD in pediatric patients between the ages of 6 and 11 years of age, can you review the evidentiary basis for this approval based on clinical trials, and the practical implications?
Uploaded: 2020-06-09T00:00:00+00:00

CLICK HERE FOR CME CREDIT Back to Symposium

Created by

Presenter

Lawrence Eichenfield, MD

Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital-San Diego
Vice Chair, Department of Dermatology
Professor of Dermatology and Pediatrics
UC San Diego School of Medicine